Coagulation: schoenwald Flashcards
Acquired Conditions and Risk Factors
- Venous stasis–> Long periods of immobilization-travel, illness
- Antiphospholipid syndrome-autoimmune
- Atrial fibrillation
-Cancer–> Mass affect pressing on vein
or Tumor produces substances promoting clotting
- Treatments (chemo/radiation)
- Trauma/surgery
Acquired Conditions and Risk Factors (cont.)
Central line catheters Pregnancy Medications Hormone replacement therapy Oral contraceptives Tamoxifen Heparin in heparin induced thrombocytopenia Atherosclerosis Obesity
Antiphospholipid syndrome= ______ antibodies
Autoimmune-cardiolipin antibodies
Antiphospholipid syndrome:
-clinical criteria=
-Vascular thrombosis-validated by imaging or biopsy
-**Pregnancy complications:
1 or more unexplained deaths of physically normal fetus at or after 10 weeks or pregnancy
1 or more premature births of physically normal newborn at or before 34 weeks due to pre-eclampsia, eclampsia or abnormally functioning placenta
3 or more unexplained consecutive miscarriages before the 10th week
Antiphospholipid syndrome:
-lab criteria
-Positive test for 1 autoantibody on 2 or more occasions 12 weeks apart
- -Lupus anticoagulant
- -Anticardiolipin antibody
- -Anti B2GP1 antibody
Antiphospholipid Syndrome: Treatment
- Lifelong anticoagulation
- *Warfarin contraindicated in pregnancy (category X)
- **Transition to LMWH during pregnancy
- NOACS?
Inherited Clotting conditions:
Factor V Leiden mutation (activated protein C resistance)
- Mutation causes single amino acid replacement at 1 of 3 cleavage sites of Factor V
- Protein C cannot inactivate the cleavage Factor V in presence of Factor V Leiden mutation-slows the clotting cascade because of persistent Factor V Leiden activity=increase in thrombin generation
- **Most common hereditary blood coagulation disorder in US-5% of Caucasians, 1.2% African Americans
Inherited Clotting conditions:
-Prothrombin ______ mutation
- *Prothrombin 20210 mutation
- -Results in increased prothrombin (Factor II)
Inherited Clotting conditions (List others)
- MTHFR mutation: Predisposes to high levels of homocysteine and MAY increase clotting risk
- Protein C: Helps regulate speed of coagulation cascade by degrading factors V and VIII
- Protein S: Cofactor with Protein C
Inherited clotting disorders:
dx by?
running factor assays or specific genetic tests
- Can be heterozygous (inherited one mutated gene copy and one normal copy) or homozygous (inherited 2 mutated gene copies)
- *Homozygous usually more severe
-Hypercoagulation panel:
Factor V Leiden
Prothrombin gene 20210 mutation
Protein C and Protein S activity
MTHFR gene-Methylenetetrahyrofolate Reductase
Homocysteine
Anticardiolipin antibodies-antiphospholipid syndrome
Hyper coag panels include?
Factor V Leiden
Prothrombin gene 20210 mutation
Protein C and Protein S activity
MTHFR gene-Methylenetetrahyrofolate Reductase
Homocysteine
Anticardiolipin antibodies-antiphospholipid syndrome
inherited clotting disorders: tx?
lifelong anticoag
Anticoagulation Agents:
describe warfarin
MOA: inhibits vitamin K dependent factors
Usage:prophylaxis and treatment of DVT and PE, afib
Only anticoagulant that prevents activation of new clotting factors
Slow onset of action: 3-5 days to become therapeutic
Stabilizes clot
Oral delivery
Multiple drug interactions
- **Therapeutic Drug Monitoring is INR
- **Reversal Agent: Vitamin K or FFP
Anticoagulation Agents:
-describe unfractionated heparin
MOA: binds to antithrombin, inhibits Factors II, IXa,Xa,Xia,XIIa
Used for prophylaxis and treatment of DVT/PE/Afib
IV
- *Monitoring PTT and CBC(HIT monitoring)
- Reversal agent-protamine sulfate
Anticoag agents:
-describe Low molecular Weight Heparin (LMWH)
=aka Dalteparin (Fragmin) or Enoxaparin (Lovenox)
- MOA :binds to antithrombin to inhibit factors Xa and Iia (mostly Xa-Xa activity of LMWH much higher than unfractionated heparin
- Used in prophylaxis and treatment of DVT/PE, unstable angina, nonQ wave MI
- Stabilizes clot
- Used with warfarin as bridge until INR therapeutic
- **May be used in pregnancy
Reversal agent is protamine sulfate